Solid Biosciences Inc. Accrued Liabilities, Current
Solid Biosciences Inc. (SLDB) had Accrued Liabilities, Current of $17.79 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $17.79M.
- 2026-03-31: Accrued Liabilities, Current $19.18M.
- 2025-12-31: Accrued Liabilities, Current $18.95M.
- 2025-09-30: Accrued Liabilities, Current $19.05M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $17.79M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $19.18M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $18.95M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $19.05M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $16.55M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $14.58M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $19.85M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $13.23M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $9.92M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $10.33M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $10.16M 10-K · filed 2025-03-06 | $10.14M 10-K · filed 2024-03-13 |
| 2023-09-30 | $11.47M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $10.51M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $12.38M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $16.69M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $10.28M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $16.14M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $9.44M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $9.53M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $8.00M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $7.71M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $6.79M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $8.64M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $8.55M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $8.31M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $8.51M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $9.18M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $11.47M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $6.01M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $7.41M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $8.23M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $5.83M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $4.94M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $4.09M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $5.97M 10-K · filed 2019-03-13 | $6.21M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |